| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $957,913 ) |
| | 2025 | 2025 | MTI BIOTECH, INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R42HL158393 | 2-HOBA for Treatment of Pulmonary Hypertension | 000 | 4 | NIH | 8/15/2025 | $957,913 |
|
| Issue Date FY: 2024 ( Subtotal = $957,913 ) |
| | 2024 | 2024 | MTI BIOTECH, INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R42HL158393 | 2-HOBA for Treatment of Pulmonary Hypertension | 000 | 3 | NIH | 8/30/2024 | $957,913 |
| | 2024 | 2021 | MTI BIOTECH, INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R41HL158393 | 2-HOBA for Treatment of Pulmonary Hypertension | 000 | 1 | NIH | 10/12/2023 | $0 |
| | 2024 | 2021 | MTI BIOTECH, INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R41CA257262 | Efficacy of an Electrophile Scavenger in the Prevention of Gastrointestinal Inflammatory Carcinogenesis | 000 | 1 | NIH | 3/26/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,173,060 ) |
| | 2023 | 2023 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R42HL158393 | 2-HOBA for Treatment of Pulmonary Hypertension | 001 | 2 | NIH | 8/24/2023 | -$1,173,060 |
| | 2023 | 2023 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R42HL158393 | 2-HOBA for Treatment of Pulmonary Hypertension | 003 | 2 | NIH | 9/6/2023 | $0 |
| | 2023 | 2023 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R42HL158393 | 2-HOBA for Treatment of Pulmonary Hypertension | 002 | 2 | NIH | 8/30/2023 | $1,173,060 |
| | 2023 | 2023 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R42HL158393 | 2-HOBA for Treatment of Pulmonary Hypertension | 000 | 2 | NIH | 8/23/2023 | $1,173,060 |
| | 2023 | 2021 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R41CA257262 | Efficacy of an Electrophile Scavenger in the Prevention of Gastrointestinal Inflammatory Carcinogenesis | 000 | 1 | NIH | 5/1/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2021 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R41HL158393 | 2-HOBA for Treatment of Pulmonary Hypertension | 000 | 1 | NIH | 12/4/2021 | $0 |
| | 2022 | 2017 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R44AG055184 | 2-Hydroxybenzylamine for the prevention of Alzheimer's disease: Initial evaluation in humans | 000 | 3 | NIH | 12/15/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $656,580 ) |
| | 2021 | 2021 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R41HL158393 | 2-HOBA for Treatment of Pulmonary Hypertension | 001 | 1 | NIH | 9/11/2021 | -$256,580 |
| | 2021 | 2021 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R41HL158393 | 2-HOBA for Treatment of Pulmonary Hypertension | 000 | 1 | NIH | 7/26/2021 | $256,580 |
| | 2021 | 2021 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R41CA257262 | Efficacy of an Electrophile Scavenger in the Prevention of Gastrointestinal Inflammatory Carcinogenesis | 002 | 1 | NIH | 4/26/2021 | $400,000 |
| | 2021 | 2021 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R41CA257262 | Efficacy of an Electrophile Scavenger in the Prevention of Gastrointestinal Inflammatory Carcinogenesis | 000 | 1 | NIH | 4/8/2021 | $400,000 |
| | 2021 | 2021 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R41CA257262 | Efficacy of an Electrophile Scavenger in the Prevention of Gastrointestinal Inflammatory Carcinogenesis | 001 | 1 | NIH | 4/22/2021 | -$400,000 |
| | 2021 | 2021 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R41HL158393 | 2-HOBA for Treatment of Pulmonary Hypertension | 002 | 1 | NIH | 9/14/2021 | $256,580 |
|
| Issue Date FY: 2020 ( Subtotal = $150,636 ) |
| | 2020 | 2017 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R44AG055184 | 2-Hydroxybenzylamine for the prevention of Alzheimer's disease: Initial evaluation in humans | 006 | 3 | NIH | 8/19/2020 | $0 |
| | 2020 | 2017 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R44AG055184 | 2-Hydroxybenzylamine for the prevention of Alzheimer's disease: Initial evaluation in humans | 005 | 3 | NIH | 12/20/2019 | $0 |
| | 2020 | 2017 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R44AG055184 | 2-Hydroxybenzylamine for the prevention of Alzheimer's disease: Initial evaluation in humans | 004 | 3 | NIH | 11/15/2019 | $150,636 |
|
| Issue Date FY: 2019 ( Subtotal = $605,216 ) |
| | 2019 | 2017 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R44AG055184 | 2-Hydroxybenzylamine for the prevention of Alzheimer's disease: Initial evaluation in humans | 002 | 3 | NIH | 7/8/2019 | $605,216 |
| | 2019 | 2017 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R44AG055184 | 2-Hydroxybenzylamine for the prevention of Alzheimer's disease: Initial evaluation in humans | 003 | 3 | NIH | 7/26/2019 | -$605,216 |
| | 2019 | 2017 | MTI BIOTECH INCORPORATED | 2711 S LOOP DR STE 4400 | AMES | IA | 50010-8656 | STORY | USA | R44AG055184 | 2-Hydroxybenzylamine for the prevention of Alzheimer's disease: Initial evaluation in humans | 004 | 3 | NIH | 8/1/2019 | $605,216 |
|
|
